12 Finance expense 2013 2012 2011 m m m Interest expense arising on: financial liabilities at amortised cost 708 731 718 derivatives at fair value through profit or loss 18 14 26 Fair value hedges: fair value movements on derivatives designated as hedging instruments 37 28 12 fair value adjustments on hedged items 36 27 11 Fair value movements on other derivatives at fair value through profit or loss 2 13 15 Unwinding of discounts on provisions 14 15 12 Movements on amounts owed to non-controlling interests 2 10 7 Other finance expense 22 24 20 767 808 799 All derivatives at fair value through profit or loss other than designated and effective hedging instruments see Note 41, Financial instruments and related disclosures are classified as held-for-trading financial instruments under IAS 39.
Interest expense arising on derivatives at fair value through profit or loss relates to swap interest expense.
13 Associates and joint ventures At 31 December 2013, the Group held one significant associate, Aspen Pharmacare Holdings Limited Aspen.
Summarised income statement information in respect of Aspen is set out below: 2013 2012 2011 m m m Turnover 1,485 1,280 1,164 Profit after taxation 247 313 216 Comprehensive income 192 163 44 Total comprehensive income 439 476 172 The results of Aspen included in the summarised income statement information above represent the estimated earnings of the Aspen group in the year, adjusted for transactions between GSK and Aspen.
Amounts relating to joint ventures principally arise from a 50% interest in one joint venture, Japan Vaccine Co. Ltd. with Daiichi Sankyo Co. Ltd. Aggregated financial information in respect of other associated undertakings and joint ventures is set out below: 2013 2012 2011 m m m Associates: Share of turnover 26 27 110 Share of after tax profits 1 5 Share of other comprehensive income Share of total comprehensive income 1 5 Joint ventures: Share of turnover 199 203 14 Share of after tax losses 2 30 31 Share of other comprehensive income Share of total comprehensive income 2 30 31 Sales to joint ventures and associates 103 124 104 GSK Annual Report 2013 151
